

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 66824

Title: Cefoperazone sodium/sulbactam sodium VS piperacillin sodium/tazobactam sodium in the treatment of respiratory tract infection in the elderly

Reviewer's code: 06060832

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: Germany

Author's Country/Territory: China

Manuscript submission date: 2021-06-02

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-07 07:44

Reviewer performed review: 2021-06-09 01:59

Review time: 1 Day and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I have read with great interest the manuscript entitled "Cefoperazone sodium sulbactam sodium VS piperacillin sodium tazobactam sodium in the treatment of respiratory tract infection in the elderly". This study selects 74 elderly patients with respiratory tract infection in their hospital for grouping study, in order to determine the therapeutic value and safety of different antibiotics. The symptom relief time, treatment effect, laboratory indexes levels before and 7 days after treatment, and the incidence of adverse reactions were calculated between the two groups. Finally, they concluded that piperacillin sodium tazobactam sodium is better than cefoperazone sodium sulbactam sodium in the treatment of senile respiratory tract infection. It can effectively relieve clinical symptoms, down-regulate the contents of serum PCT, CRP and other factors, reduce the degree of inflammatory reaction, and has a certain degree of safety. The authors present an interesting study that is well motivated and designed. Their data is well presented and their conclusions largely follow from this data. Thank you for giving opportunity to review this study. However, the following points must be considered before publication.

- Modify the description of some errors in the article: e.g., Page 1 Line 19-20, ...study group (90.48%) control group (71.43%), ... (P= 0.710). should be "study group (94.59%) and control group (75.68%), P=0.022"; Page 4 Line 11, should fill in the missing P value. Please check the full text.
- Detailed description of the adverse events that occurred in the study.
- English language correction through the manuscript.
- Discuss merits and limitations of this study.